Literature DB >> 35670971

Concepts of Pathological Staging and Prognosis in Papillary Thyroid Carcinoma.

Alfred K Lam1,2,3.   

Abstract

American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (AJCC/UICC) staging and American Thyroid Association (ATA) risk predication system are the best predicators of mortality and cancer recurrence, respectively, in patients with differentiated thyroid carcinoma, including papillary thyroid carcinoma. In ATA risk stratification of differentiated thyroid carcinomas, clinical features, nodal features, and pathological features are assessed. Many of the features are also assessed in pathological staging. The prognostic stage grouping of papillary thyroid carcinoma in AJCC/UICC depends on the age of the patients as well as the standard parameters-extent of tumor (T), lymph node status (N), and presence of distant metastasis (M). Major changes noted in the current pathological staging protocol include the cut-off age from 45-year to 55-year in grouping of patients, use of gross invasion of strap muscles instead of minimal microscopic extrathyroidal extensions as T3b and downstage of many prognostic groups such as those with lymph node metastases (without distant metastases) from Stage III to Stage II. The staging protocol have moved many patients with papillary thyroid carcinoma into good prognostic groups for better predication of patients' survival rates and to avoid unnecessary treatment. This new approach has been verified by different groups globally, although modifications could be expected in the future for better prognostic assessment in patients with papillary thyroid carcinoma.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  AJCC; Papillary thyroid carcinoma; Pathology; Staging; Thyroid

Mesh:

Year:  2022        PMID: 35670971     DOI: 10.1007/978-1-0716-2505-7_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  34 in total

1.  Risk of Recurrence in Differentiated Thyroid Cancer: A Population-Based Comparison of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Systems.

Authors:  Tong Gan; Bin Huang; Quan Chen; Heather F Sinner; Cortney Y Lee; David A Sloan; Reese W Randle
Journal:  Ann Surg Oncol       Date:  2019-03-04       Impact factor: 5.344

2.  Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.

Authors:  K Y Lam; C Y Lo; K W Chan; K Y Wan
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

3.  Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma.

Authors:  Jingtai Zhi; Yu Wu; Linfei Hu; Jingzhu Zhao; Hui Liu; Xianhui Ruan; Xiukun Hou; Jun Zhang; Xiangqian Zheng; Ming Gao
Journal:  Int J Clin Oncol       Date:  2019-08-14       Impact factor: 3.402

4.  Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system.

Authors:  N Chereau; T O Oyekunle; A Zambeli-Ljepović; H S Kazaure; S A Roman; F Menegaux; J A Sosa
Journal:  Br J Surg       Date:  2019-04-23       Impact factor: 6.939

5.  Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability.

Authors:  Brian Lang; Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg Oncol       Date:  2007-02-21       Impact factor: 5.344

6.  Evaluating the predicted impact of changes to the AJCC/TMN staging system for differentiated thyroid cancer (DTC): A prospective observational study of patients in South East Scotland.

Authors:  Kate Hulse; Adam Williamson; Fraser W Gibb; Brendan Conn; Iain J Nixon
Journal:  Clin Otolaryngol       Date:  2019-03-04       Impact factor: 2.597

7.  Survival in differentiated thyroid carcinoma: A comparison between the 7th and 8th editions of the AJCC/UICC TNM staging system and the ATA initial risk stratification system.

Authors:  Beatriz Godoi Cavalheiro; Leandro Luongo de Matos; Ana Kober Nogueira Leite; Marco Aurelio Vamondes Kulcsar; Claudio Roberto Cernea; Luiz Paulo Kowalski
Journal:  Head Neck       Date:  2021-06-01       Impact factor: 3.147

8.  How Does The AJCC/TNM Staging System Eighth Edition Perform in Thyroid Cancer at A Major Middle Eastern Medical Center?

Authors:  Ali S Alzahrani; Lina Albalawi; Sedra Mazi; Noha Mukhtar; Hadeel Aljamei; Yosra Moria; Tarek Elsayed; Lama Amer; Faisal Alanazi; Layla Alnasser; Bayan Alqarni; Roqyah Fadel; Ahmed AlMatar; Ashwag Alqahtani; R Michael Tuttle
Journal:  Endocr Pract       Date:  2020-12-14       Impact factor: 3.443

9.  Impact of the change from the seventh to eighth edition of the AJCC TNM classification of malignant tumours and comparison with the MACIS prognostic scoring system in non-medullary thyroid cancer.

Authors:  S Dwamena; N Patel; R Egan; M Stechman; D Scott-Coombes
Journal:  BJS Open       Date:  2019-06-28

10.  Impacts of the American Joint Committee on Cancer (AJCC) 8th edition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients.

Authors:  Yotsapon Thewjitcharoen; Waralee Chatchomchuan; Krittadhee Karndumri; Sriurai Porramatikul; Sirinate Krittiyawong; Ekgaluck Wanothayaroj; Siriwan Butadej; Soontaree Nakasatien; Veekij Veerasomboonsin; Auchai Kanchanapituk; Rajata Rajatanavin; Thep Himathongkam
Journal:  Heliyon       Date:  2021-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.